In this phase 2 trial, a combination of osimertinib and bevacizumab was administered to patients with previously untreated stage IV or relapsed EGFR-mutated NSCLC complicated by malignant pleural or pericardial effusion. The gene discussed is EGFR; the disease is pericardial effusion.